VivoCAR™ Anti-CD22 (hRFB4) h(CD28-41BB-CD3z) CAR saRNA (XS-0326-XU13)

Name: VivoCAR™ Anti-CD22 (hRFB4) h(CD28-41BB-CD3z) CAR saRNA
SKU: XS-0326-XU13
Rating: 5 (1 reviews)

Online Inquiry Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

VivoCAR™ Anti-CD22 (hRFB4) h(CD28-41BB-CD3z) CAR saRNA utilizes the saRNA platform to drive expression of the humanized RFB4 (hRFB4) clone. In vivo CAR-T therapy relies on the hRFB4 clone for its superior internalization properties and high affinity for CD22. The saRNA's intracellular replication mechanism provides a "biological magnification" effect, ensuring that T cells express enough CAR molecules to trigger efficient lysis even when CD22 expression is relatively low, offering a potent solution for B-cell malignancies that have escaped CD19-targeted therapies.

Add to Cart

CAR Information

Target
CD22

Target Species
Human

Antibody Clone
hRFB4

scFv Host Species
Human

Receptor Construction
CD28-41BB-CD3z

Generation
Third

Description of Signaling Cassetes
The third-generation CD28-41BB-CD3ζ architecture employs a sequential costimulatory strategy, where the CD28 module drives rapid initial activation and metabolic reprogramming, while the 4-1BB component sustains long-term cellular viability and mitigates exhaustion. This tandem design, anchored by the CD3ζ signaling chain, synergistically amplifies downstream signal transduction, resulting in a balanced T-cell phenotype with robust effector capacity and prolonged durability. The integrated signaling cascade thus optimizes both kinetic expansion and persistence, enhancing antitumor efficacy.

CAR saRNA Properties

Structure
Linear

Cap
Cap 1

PolyA
Segmented PolyA

Product Type
CAR IVT saRNA

Concentration
Lot specific

Buffer
1 mM Sodium Citrate, pH 6.4 (or specialized RNA storage buffer, RNase-free).

Storage
Aliquot and store at -80°C. Avoid freeze/thaw cycles.

Handling
Thaw and work with RNA on ice. Upon first use, pulse spin before opening and aliquot into single use portions. DO NOT vortex. Use only certified RNase-free reagents and consumables with proper RNase-free technique. Use of barrier tips is recommended. Avoid freeze/thaw cycles. DO NOT mix with media containing serum unless first complexed with a stabilizing transfection reagent.

saRNA Quality Control

IVT Vector Sequencing
Pass

IVT Vector Enzyme Digestion
Pass

Purity OD260/280
Pass

RNA Length and Integrity Assessment (Determined by Denaturing Agarose Gel Electrophoresis)
Pass

RNA Sequence Assessment
Pass

Endotoxin (<10 EU/mg)
Pass

In Vitro Transfection and Expression (Optional)
Pass

Target Information

Full Name
B-cell receptor CD22

Alternative Names
SIGLEC2; SIGLEC-2; B-lymphocyte cell adhesion molecule; B-cell receptor CD22

Introduction
CD22 is a 140 kDa sugar-binding transmembrane protein specifically expressed on the surface of mature B cells and most B-cell lineage malignancies. It functions as an inhibitory co-receptor of the B-cell receptor (BCR) and belongs to the SIGLEC family. Unlike CD19, CD22 is rapidly internalized upon binding, making it an excellent target for both CAR-T therapies and immunotoxins. Its expression is often maintained even after CD19 loss, making it a critical secondary target in CAR therapy.

Targeting Diseases
B-cell Acute Lymphoblastic Leukemia (B-ALL), Non-Hodgkin Lymphoma (NHL)

UniProt ID
P20273

Gene ID
933

Related Resources

Overview of CD22-Targeted CAR Cell Therapies

Case Studies

Customer Reviews and Q&As

There are currently no customer reviews or questions for VivoCAR™ Anti-CD22 (hRFB4) h(CD28-41BB-CD3z) CAR saRNA (XS-0326-XU13). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.